[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Walter Reed National Military Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":429},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,40,63,92,123,161,186,219,242,266,292,314,335,363,384,409],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100531828","new-approaches-to-nerve-stimulation-therapy-for-bladder-pain-syndrome-100531828",false,"NCT06204874","New Approaches to Nerve Stimulation Therapy for Bladder Pain Syndrome","Evaluation of Pulsed Radiofrequency Ablation of the Superior Hypogastric Plexus for Treatment of Bladder Pain Syndrome: A Case Series","Inclusion Criteria:\n\n* Female sex\n* Age greater than or equal to 18\n* Diagnosis of Bladder Pain Syndrome as evidenced by score greater than or equal to six on O'Leary-Sant Voiding and Pain Indices\n* DEERS-eligible health care beneficiaries\n\nExclusion Criteria:\n\n* Patients with current enabled implantable neurostimulation (i.e. transcutaneous electrical nerve stimulation unit, Interstim)\n* Current active pelvic or gynecologic malignancy\n* Coagulation disorder\n* Local infection at injection site\n* Sepsis\n* Decompensated cardiac or hemodynamic disorders\n* Neurogenic bladder and patients with spinal cord injury\n* Current pregnancy\n* Structural abnormalities of the spine that prevent performance of the procedure\n* Intravesical onabotulinumtoxin A injection within the last 3 months","FEMALE","18 Years",{"count":19,"type":20},5,"ESTIMATED","INTERVENTIONAL",[23],"NA","Many women suffer from bladder pain syndrome (BPS). There are many treatments, but there is no one universally effective option. The goal of this clinical trial is to explore the use of electrical energy directed towards a group of nerves, called the superior hypogastric plexus, for treatment of BPS in women over the age of 18 with a diagnosis of BPS. The main question it aims to answer is: does use of electrical micro-current directed at the superior hypogastric plexus improve pain associated with BPS?\n\nThere is data from many different studies that suggest that this kind of therapy might provide relief of BPS symptoms.\n\nParticipants will be asked to participate for a total of six months from the date of their first nerve treatment. At the first appointment, they will be evaluated in the Walter Reed Chronic Pain clinic and asked several questions about the severity and personal management of their symptoms. The procedure will then be performed by inserting two needles into the back (one on either side of the spine) and directing extremely short bursts of electrical micro-current towards the target nerve. The medical term for this is \"pulsed radiofrequency ablation.\" This procedure causes disruption on a microscopic level of nerve fibers that send pain sensations to the bladder and other organs in the pelvis. Following this initial appointment, participants will be asked about their symptoms at 1-, 3-, and 6-month follow-up appointments. Participants will be asked about pain, mood symptoms, sexual function, and measures of bladder irritation. The procedure will only be performed once.\n\nAt the study conclusion, researchers will analyze pain scores, as well as other secondary outcomes listed above.\n\nBenefits of this study may include possible relief of BPS symptoms. This may help to advance research about treatments for BPS. This is a novel approach to the treatment of BPS and as such may provide benefits greater than those found in treatment outside of the study.",[26],"Bladder Pain Syndrome","RECRUITING","2026-04-25",{"date":30,"type":31},"2026-04-30","ACTUAL",{"date":33,"type":31},"2024-01-01",{"date":35,"type":20},"2026-12",{"name":37,"class":38},"Walter Reed National Military Medical Center","FED",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":60,"leadSponsor":62,"locationsCount":39},"100530138","tender-loving-care-for-recurrent-pregnancy-loss-100530138","NCT06182878","Tender Loving Care for Recurrent Pregnancy Loss","A Single-arm Trial of a Web Based TLC (Tender Loving Care) Platform to Psychologically Support Patients With Recurrent Pregnancy Loss","Inclusion Criteria:\n\n* Pregnant individuals receiving their prenatal care at WRNMMC\n* Able to speak and understand English\n* Less than or equal to 10+0 weeks gestation by last menstrual period (LMP) or dating ultrasound at the time of enrollment\n* At least two prior pregnancy losses. Pregnancy losses must be confirmed with laboratory criteria confirming a positive pregnancy test in the military electronic medical record with subsequent resolution (resolution may be reported by patient), or with ultrasound criteria demonstrating an intrauterine gestational sac with subsequent resolution (resolution may be reported by patient).\n\nExclusion Criteria:\n\n* Age less than 18 years and older than 44 at time of enrollment\n* Unable to speak or understand English\n* Current smoker or tobacco use within 30 days\n* History of uterine anomaly, coagulopathy, balanced translocation, endometrial polyps, submucosal fibroids, pathology confirmed acute or chronic endometritis, hydrosalpinx, history of Asherman syndrome, poorly controlled endocrinopathies, HIV infection\n* History of gonadotoxic therapy or cancerous condition of the female reproductive tract\n* Suspicion for or confirmation of an ectopic pregnancy",true,"44 Years",{"count":50,"type":20},60,[23],"The goal of this investigational study is to evaluate participation in a weekly, interactive, tender loving care messaging platform impact on pregnancy outcomes in patients with recurrent pregnancy loss.\n\nThe main questions it aims to answer are: (1) does participation in weekly, interactive tender loving care messages increase live birth rates in patients with recurrent pregnancy loss? (2) Does participation in weekly, interactive tender loving care messages increase patients' quality of life? Does participation in weekly, interactive tender loving care messages decrease patients' depressive symptoms?\n\nParticipants will be asked to interact with weekly messages providing prenatal counseling and support. Additionally, patients will be asked to complete the fertility quality of life survey several times over the course of the pregnancy.",[54],"Recurrent Pregnancy Loss",[54],"2026-04-17",{"date":58,"type":31},"2026-04-22",{"date":33,"type":31},{"date":61,"type":20},"2026-12-01",{"name":37,"class":38},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":21,"phases":76,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},"100564973","transtibial-osseointegration-100564973","NCT06636136","Transtibial Osseointegration","Transtibial Osseointegration Surgery Study (TOSS)","TOSS","Inclusion Criteria:\n\n* Diagnosis of a transtibial amputation age 22-65.\n* The OPRA™ Implant System is indicated for patients who have transtibial amputation due to trauma or cancer and who have or are anticipated to have rehabilitation problems with, or cannot use, a conventional socket prosthesis. The OPRA™ Implant System is intended for skeletally mature patients.\n* The patient failed to receive benefit from socket prostheses or is expected to not tolerate socket use due to problems such as:\n\n  * Recurrent skin infections and ulcerations in the socket contact area\n  * Pain\n  * A short stump preventing the use of socket prosthesis\n  * Volume fluctuation in the stump\n  * Soft tissue scarring\n  * Extensive area of skin grafting\n  * Socket retention problems due to excessive perspiration\n  * Restricted mobility\n* Eligible to receive care at Military Treatment Facility ( WRNMMC only)\n* DEERS-eligible ( WRNMMC only)\n\nExclusion Criteria:\n\n* The patient's skeletal growth is not complete. Completed skeletal growth is defined through the finding of generally closed epiphyseal zones on X-ray.\n* The patient has atypical skeletal anatomy which may affect treatment with OPRA™.\n\n  * Examples of atypical skeletal anatomy.\n  * Skeletal dimensions outside defined interval.\n  * Development anomalies.\n  * Conditions which are not amenable to device insertion such as deformities, fracture, infection.\n* The patient would have less than 2 mm of remaining cortex bone available around the implant, if implanted.\n* Osteoporosis.\n* The patient is older than 65 years and younger than 22 years.\n* BMI over 35.\n* Do not treat patients with the following concurrent diseases:\n\n  * Severe peripheral vascular disease.\n  * Diabetic mellitus with complications.\n  * Neuropathy or neuropathic disease.\n  * Active infection or dormant bacteria.\n  * Metabolic bone disease and\u002For metastatic lesions in the residual tibia.\n* Pregnancy before the surgery female patients will take a pregnancy test) Note: Patients who become pregnant, after surgery stage I, surgery stage II will be delayed until safe to do so by their doctor. The patient will remain in the study, unless they would like to withdrawal.\n* The patient is not expected to be able to comply with treatment and follow up requirements.\n* Participants unable to sign their own consent (No legally authorized representatives may provide consent)","ALL","22 Years","65 Years",{"count":75,"type":20},30,[23],"Purpose:\n\nAim 1: Quantify soft tissue complications and infections of service members with transtibial amputations treated with OPRA OI and compare them to transfemoral OI service members.\n\nAim 2: Compare the validated domains, such as functional, quality of life and pain scores, from the preoperative baseline to follow-up visits to determine if persons with transtibial amputations treated with OPRA osseointegrated prostheses demonstrate statistically significant and clinically relevant improvements.\n\nAim 3: Compare physical performance measures preoperatively to follow-up visits for persons with transtibial amputations treated with OPRA osseointegrated prostheses to quantify statistically significant and clinically relevant improvements.\n\nAim 4: Quantify the biomechanical loading and bone quality changes that are directly associated with patient reported outcomes for persons with transtibial amputations treated with OPRA osseointegration.\n\nAim 5: Compare outcome measures between persons with traditional socket prostheses (patients as self-controls) and OPRA OI devices as well as a comparison between persons with transtibial OI and transfemoral OI.\n\nSubject Population:\n\nMale and female military health care beneficiaries age 22 to 65 years old presenting with a Transtibial limb loss.\n\nStudy Design:\n\nThis is a 4-year, prospective cohort FDA pivotal study involving off-label use of the OPRA OI implant in persons with transtibial amputation.\n\nProcedures:\n\nSURGICAL PROCEDURES:\n\nSurgery Stage I:\n\nThe distal part of the tibia is exposed, preferably using existing incisions, to produce an appropriate fasciocutaneous flap. By the use of fluoroscopy and guiding devices the correct position of the fixture in the medullary canal is found. The canal is reamed step by step to a proper diameter to facilitate insertion of the implant. If the bone quality is poor, as determined by the operating surgeon, autologous bone graft from the iliac crest and\u002For the medullary canal is used. The fixture is then implanted into the intramedullary canal. Careful surgical technique is essential not to damage the tissue and to achieve osseointegration. A central screw, healing cylinder, and healing bolt are inserted. A myodesis is performed, and the wound is closed using suture.\n\nThe sutures are removed 2-3 weeks postoperatively. When the skin is completely healed the Patient's conventional socket prosthesis could, in some instances, be used.\n\nSurgery Stage II (3-5 months after Stage I):\n\nThe tibia is exposed via the incision from the Stage I-Surgery. The healing cylinder is removed and the tissues are trimmed in a way that the distal end of the bone protrudes a few millimeters. The skin will be attached directly to it. The endosteal canal is reamed to facilitate placement of the abutment. The skin in the abutment area is then trimmed to a diameter equal to the protruding end of the tibia. This is done to remove the subcutaneous fat and facilitate healing of the dermal layer to the distal end of the bone. The subcutaneous tissue is affixed to the periosteum using absorbable suture to prevent skin movement. A 8mm punch biopsy tool is used to create a circular hole in the skin precisely over the residual tibial canal. The remaining portion of the fasciocutaneous flap is sutured into position. A bolster dressing is placed and routine postoperative wound care is performed by daily dressing changes. Sutures are removed 2-3 weeks postoperatively.\n\nCLINICAL PROCEDURES\n\nA pre-study visit will be conducted up to 6 months prior to Surgery Stage I. Postoperative visits will occur 2-3 weeks after each surgery. Additional follow-up visits will occur 6, 12, 24, 36, 48 and 60 months post-Surgery Stage II. It is standard of care to follow patients postoperatively from time to time to ensure the wound(s) is \u002Fare healing, surveil for complications, and ensure rehabilitation is progressing. That said, the sole reason for engaging in the Clinical Follow-Up Procedures is for the purpose of conducting research under this particular protocol. Additional visits may occur including x-rays at the discretion of the clinical investigator in order to monitor the participants medical status\u002Fbone healing.\n\nRESEARCH PROCEDURES\n\nTimepoints: Baseline, Post-Op Stage II, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months\n\nThe patients will be assessed before and after the surgery regularly. Both performance and safety data will be recorded on specially designed electronic Case Report Forms (eCRFs). Clinical and radiological assessments are performed preoperatively (in connection with the surgical procedures.",[79],"Amputation; Traumatic, Leg, Lower",[81,82],"Transtibial","Osseointegration","2026-03-24",{"date":85,"type":31},"2026-03-30",{"date":87,"type":31},"2025-05-20",{"date":89,"type":20},"2030-04-30",{"name":37,"class":38},2,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":47,"sex":71,"minAge":17,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},"100448689","post-concussion-musculoskeletal-injury-risks-100448689","NCT05122728","Post-Concussion Musculoskeletal Injury Risks","Post-Concussion Neuromuscular Function and Musculoskeletal Injury Risk","Inclusion Criteria:\n\nConcussed Cohort\n\n* 18-40 years old.\n* Self-reported asymptomatic post-concussion following enrollment into the study and monitoring of symptoms by research personnel via daily self-reported symptom questionnaires.\n* Recruited within 5 days following being diagnosed with a concussion, and at least 72 hours prior to self-reporting as asymptomatic.\n* Access to a functional email address and the internet for completion of patient reported outcomes (PROs) and musculoskeletal injury measures.\n\nNon-Concussed Cohort\n\n* 18-40 years old.\n* Active duty Service members and physically active civilians.\n* No self-report history of concussion within the previous 5 years.\n* No lingering post-concussion signs\u002Fsymptoms.\n* Same gender as the matched concussed participant.\n* Within ±5% of the matched concussed participant's height, weight, and body mass index.\n* Within ±2 years of age of the matched concussed participant.\n* Participant in the same physical activities (work, recreational sports, average type \\[no impact, low-impact, high-impact\\] and duration of physical activity)\n\nExclusion Criteria:\n\n* Post-Concussion Cohort AND Healthy Non-Concussed Cohort\n\n  * Unable to read or comprehend the English language.\n  * Admitted to the hospital following concussion.\n  * Sustained a concussion not related to physical activity participation (e.g., blast-related injury, fall from a ladder, motor vehicle accident).\n  * Loss of consciousness longer than 30 minutes.\n  * Alteration in consciousness longer than 24 hours.\n  * Post-traumatic amnesia lasting longer than 1 day.\n  * Glasgow Coma Scale below 13.\n  * Abnormal brain imaging findings.\n  * Sustained a concussion that took longer than 21 days for the individual to report as asymptomatic.\n  * A MSKI within the last 6 months that resulted in altered or missed physical activity for 3 or more consecutive days.\n  * History of MSKI surgery.\n  * Pregnant females (will be eligible for participation in the study once medically cleared to RTD\u002FA by a qualified and licensed healthcare provider following the end of the pregnancy).\n  * Participants will be excluded if they present any known contraindications for electrical stimulation. These contraindications include conditions such as: active deep vein thrombosis\u002Fthrombophlebitis, any acute injury with concurrent inflammation, hemorrhagic conditions, impaired circulation, impaired local sensations, presence of infection (osteomyelitis, tuberculosis), malignancy, recently radiated tissue, skin disease\u002Fdamage and\u002For at-risk skin.\n  * Present with any implanted pacemaker, electronic device, or plastic\u002Fcement material","40 Years",{"count":101,"type":20},148,"OBSERVATIONAL","Musculoskeletal injuries (MSKI) and traumatic brain injury (TBI) are the signature injuries of the ongoing military conflicts. MSKI affect 800,000 Service Members annually and TBI have impacted more than 350,000 in the past 19 years and account for 22% of all combat casualties. Concussion, a mild form of TBI, increases MSKI risk in physically active individuals, including Service Members.\n\nThe overall goal of the study is to identify the neuromuscular control mechanisms that increase MSKI risk following concussion. It is hypothesized that concussed individuals will display abnormal neuromuscular function that increases MSKI risk, as compared to non-concussed controls. The study will employ a multi-center, prospective, case-matched control observational study to identify the differences in neuromuscular function following concussion that may contribute to increased MSKI risk. Once the neuromuscular control mechanisms that increase MSKI risk following concussion are identified, targeted risk mitigation strategies can be developed to reduce MSKI risk.",[105],"Musculoskeletal Injury",[107,108,109,110,111,112,113],"musculoskeletal injury","biomechanics","movement assessment","neuromuscular control","traumatic brain injury","TBI","concussion","2026-01-23",{"date":116,"type":31},"2026-01-27",{"date":118,"type":31},"2022-10-20",{"date":120,"type":20},"2027-09-30",{"name":37,"class":38},3,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":71,"minAge":17,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":21,"phases":132,"briefSummary":133,"conditions":134,"keywords":150,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":91},"100471118","art-therapy-and-emotional-well-being-in-military-populations-with-posttraumatic-stress-symptoms-100471118","NCT05414708","Art Therapy and Emotional Well Being in Military Populations With Posttraumatic Stress Symptoms","Inclusion Criteria:\n\n* DEERS Eligible\n* Active Duty or Veteran separated within the past 10 years\n* Significant posttraumatic stress symptoms (score of \\>\u002F=31 on the PCL-5)\n\nExclusion Criteria:\n\n* History of moderate, severe, or penetrating brain injury\n* History of psychotic disorder, bipolar disorder, or active suicidal or homicidal ideation\n* History of multiple sclerosis, Huntington's disease, or Alzheimer's disease\n* History of stroke or myocardial infarction\n* History of brain tumor\n* History of seizures\n* Contradictions for MRI (for example, participants will be excluded for pregnancy, metal implants or suspected shrapnel, aneurysm\u002Fintracranial clips, cardiac pacemakers or implanted programmable devices or pumps)\n* Unable to provide informed consent\n* History of previous exposure to art therapy\n* Active substance use disorder","64 Years",{"count":131,"type":20},40,[23],"Art therapy is used across the Military Health System for treatment of posttraumatic symptoms, but there is limited research on how art therapy is able to restore emotional expression and regulation in service members. This research hopes to learn about the effects of art therapy on emotional expression and regulation in service members as well as the neurological systems at work. If a participant chooses to be in this study, he or she will attend eleven sessions over a period of six to eight months. The first session will be an interview and self-assessment questionnaires to collect information on a variety of symptoms, experiences, and personality traits, and an MRI scan. During the MRI scan, participants will be asked to perform a task where they will be shown a series of neutral and negative images. The following eight sessions will be one-hour art therapy sessions with a certified art therapist. The tenth session will consist of the same self-assessment questionnaires and another MRI scan. The final session will consist of some of the same questionnaires from the tenth visit, as well as a qualitative interview done virtually three months after the tenth visit.",[135,136,137,138,139,140,141,142,143,144,145,146,147,148,149],"PTSD","Military Activity","Post-Traumatic Headache","Posttraumatic Stress Disorder","Posttraumatic Stress Disorder, Delayed Onset","Sleep Disturbance","Nightmare","Irritable Mood","Anger","Combat and Operational Stress Reaction","Combat Stress Disorders","Military Family","Military Operations","Emotional Regulation","Emotion Processing",[135,151,152],"Military","Art Therapy","2026-01-06",{"date":155,"type":31},"2026-01-08",{"date":157,"type":31},"2022-02-01",{"date":159,"type":20},"2027-12",{"name":37,"class":38},{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":71,"minAge":17,"maxAge":167,"enrollmentInfo":168,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":170,"conditions":171,"keywords":175,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":39},"100518743","cognitive-and-vascular-functioning-following-tbi-100518743","NCT06034509","Cognitive and Vascular Functioning Following TBI","Inclusion Criteria:\n\n1. Active duty uniformed SM or Veteran who is currently eligible for treatment at WRNMMC (i.e., Defense Enrollment Eligibility Reporting System (DEERS)-eligible).\n2. Ability to read, write, and speak English.\n3. Ability to provide informed consent.\n4. NICoE Intensive Outpatient Program (IOP) or NatHx Study comprehensive evaluation ≥3 years prior to current evaluation with valid neuropsychological test results.\n5. Consent to allow access to prior research data collected through the NICoE TBI Neuroimaging Core Project or NatHx Study and consent to allow access to at least 1 prior blood specimen previously collected through these studies or the DoD Serum Biorepository.\n\nAdditional TBI Inclusion Criteria\n\n1\\. History of at least one mild, moderate, severe, or penetrating TBI \\> 3 years prior to enrollment. TBI will be diagnosed if any one of the following criteria immediately after the injury is met and attributed to the brain injury, rather than environmental\u002Fpsychological\u002Fother injury factors (DoD-VA criteria246):\n\n1. Loss of consciousness (LOC) or post-traumatic amnesia (PTA)\n2. Alteration of consciousness (AOC)\n3. Evidence of neurologic dysfunction\n4. TBI-related abnormality on structural neuroimaging (either CT or MRI). Additional Healthy Control Criteria\n\n   1. History of military deployment.\n   2. Low history of blast exposure (i.e., \\\u003C10 blasts) Additional Blast Control Criteria\n\n   \u003C!-- -->\n\n   1. History of significant blast exposure (i.e., exposure to ≥ 10 blasts)\n\nExclusion Criteria:\n\n1. Disabling neurologic or psychological disorders such as autism, cerebral palsy, developmental disorder, stroke, brain tumor, multiple sclerosis, meningitis, encephalitis, brain abscess, vascular malformation, pre-injury epilepsy, schizophrenia, bipolar disorder, personality disorder\n2. Diabetes mellitus requiring drug treatment\n3. Hypertension requiring more than 1 antihypertensive drug to control BP\n4. History of myocardial infarction or other systemic vasculopathies\n5. Dementia diagnosis at initial NICoE\u002FNatHx Study assessment","74 Years",{"count":169,"type":20},300,"This observational study will examine the association of chronic traumatic cerebrovascular injury and cardiovascular risk factors with TBI-related cognitive impairment and vascular dementia. Cerebrovascular, inflammatory, and neurodegenerative blood biomarkers as well as clinical and neuroimaging data",[172,173,174],"Traumatic Brain Injury","Cognitive Decline","Vascular Dementia",[172,173,174,176,177,151],"Blood Biomarkers","Cerebrovascular Reactivity","2025-09-22",{"date":180,"type":31},"2025-09-26",{"date":182,"type":31},"2023-11-27",{"date":184,"type":20},"2027-05",{"name":37,"class":38},{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":71,"minAge":17,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":21,"phases":196,"briefSummary":199,"conditions":200,"keywords":204,"overallStatus":210,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":39},"100604584","phase-2-use-of-corticosteroid-in-intraopertive-injections-in-total-knee-replacement-surgery-100604584","NCT07151417","Use of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery.","Adjunctive Use of Corticosteroid in Periarticular Injections in Primary Total Knee Arthroplasty","TKACSI","Inclusion Criteria:\n\n* Patients within the MHS who are DEERS eligible undergoing primary TKA at Walter Reed National Military Medical Center (WRNMMC), Surgery Center of Chevy Chase or District Surgery Center\n* Age 18 or older\n* successful surgical intervention\n\nExclusion Criteria:\n\n* Unicompartmental knee arthroplasty (UKA)\n* Revision total knee arthroplasty (rTKA)\n* Females who are pregnant or nursing\n* Allergic to ingredients in PAI or previous adverse reaction to steroids being used in this study\n* Diabetics will be excluded from Group 2 (standard PAI + methylprednisolone)",{"count":195,"type":20},240,[197,198],"PHASE2","PHASE3","The goal of this clinical trial is to find out which type of steroid medicine, when added to a standard pain-control injection during total knee replacement surgery, works best at reducing pain, limiting opioid use, and improving recovery in adults undergoing surgery for severe knee arthritis or injury.\n\nThe main questions it aims to answer are:\n\nDoes adding a steroid to the injection improve pain control and reduce opioid use after surgery? Is the newer extended-release steroid (Zilretta) more effective and safer-especially for patients with diabetes-than the traditional steroid (methylprednisolone)?\n\nResearchers will compare:\n\nStandard pain-control injection alone Standard injection plus methylprednisolone Standard injection plus Zilretta to see which option provides better pain relief, less opioid use, and improved knee function.\n\n(Patients with diabetes or prediabetes will only be in the standard injection or Zilretta groups so researchers can study whether Zilretta is safer for blood sugar control.)\n\nParticipants will:\n\nBe randomly assigned to one of the study groups during their total knee replacement surgery Receive the assigned pain-control injection around the knee joint\n\nBe followed after surgery to measure:\n\nPain levels Opioid pain medication use Knee movement (range of motion) Whether another procedure (such as manipulation under anesthesia) is needed if the knee becomes too stiff Patient-reported outcome surveys about pain and function",[201,202,203],"Knee Osteoarthritis","Musculoskeletal Disease","Surgery",[205,206,207,208,209],"total knee arthroplasty (TKA)","manipulation under anesthesia (MUA)","corticosteroid","periarticular injection\u002Fpericapsular injection (PAI)","zilretta","NOT_YET_RECRUITING","2025-08-28",{"date":213,"type":31},"2025-09-03",{"date":215,"type":20},"2025-09-01",{"date":217,"type":20},"2026-08-31",{"name":37,"class":38},{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":71,"minAge":17,"maxAge":227,"enrollmentInfo":228,"targetDuration":230,"studyType":102,"phases":4,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":39},"100539930","microbiome-population-adaptation-study-100539930","NCT06310239","Microbiome Population Adaptation Study","Osseointegrated Limb Implant Microbiome Population Adaptation Study","OLIMPAS","Inclusion Criteria:\n\n* Any adult male or female that will undergo an OI procedure between the ages of 18-75.\n* Defense Enrollment Eligibility Reporting System (DEERs) eligible\n\nExclusion Criteria:\n\n* Inability to provide self-consent","75 Years",{"count":229,"type":20},50,"24 Months","The investigators will accomplish our research aims by collecting cutaneous microbiome samples from 50 persons that have undergone the Osseointegration (OI) surgery at eight timepoints, prospectively. The investigators will also collect control samples to correct for turnovers in species compositions that may naturally occur and to compare the residual limb microbiome to the sound contralateral limb. The investigators will sequence the bacterial community using universal bacterial primers. Using these sequences, The investigators will borrow from ecological theory and calculate the alpha and beta diversity. The alpha diversity will determine the species and abundance of each species that are present, while the beata diversity will allow us to compare how species assemblages and frequencies change between time points. Then, the investigators will take a phylogenetic modeling approach to determine if particular species assemblages correlate with rates of wound healing. The investigators will construct phylogenies from the sequences at the different time points and \"paint\" the rate of wound healing along the phylogeny (e.g., improved, stagnated, worsened). Using Akaike and Bayesian information criterion, the investigators can determine which phylogenetic model best explains the patterns the investigators see across patients. Lastly, the investigators will quantify soft tissue stability and health and correlate this with the homeostasis of the microbial community. Specifically, the investigators will determine if redundant soft tissue leads to altered microbial communities that can impact the rate of wound healing. Finally, the investigators will further stratify these data to compare microbial communities between the sexes, upper versus lower limbs, and proximal versus distal amputations. This work will allow us to better treat infections after OI surgery and can shed light on wound healing process so that the investigators can better treat limb loss patients and the military community as a whole.",[233],"Amputation With Osseointegration","2025-08-25",{"date":236,"type":31},"2025-08-26",{"date":238,"type":31},"2023-12-01",{"date":240,"type":20},"2029-11-30",{"name":37,"class":38},{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":47,"sex":71,"minAge":17,"maxAge":73,"enrollmentInfo":249,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":251,"conditions":252,"keywords":255,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":39},"100535087","the-effect-of-sex-steroid-replacement-therapy-in-the-hypogonadism-and-transgender-active-duty-population-100535087","NCT06247267","The Effect of Sex Steroid Replacement Therapy in the Hypogonadism and Transgender Active-Duty Population","The Effect on Sex Steroid Replacement Therapy in the Hypogonadism and Transgender Active-Duty Population on Bone Density, Fractures, Memory\u002FCognitive Function and Qualities of Life","Inclusion Criteria:\n\n* Male and female DoD health care beneficiaries\n* Ages 18-65\n* Diagnosed with primary hypogonadism or transgender treatment for at least 6 months\n* Under care for gender identity dysphoria\n* On stable dose of sex steroid hormonal therapy for at least 6 months prior to enrolling\n* Must be living in the Washington, D.C. area for at least 12 months following enrollment\n\nExclusion Criteria:\n\n* Pregnancy, plan for pregnancy in the next 12 months\n* Cardiac disease, especially coronary artery disease\n* Malabsorption disorder\n* Gastrointestinal surgeries\n* Significant renal or liver dysfunction\n* Seizure disorders\n* recent orders to move out of the geographic area\n* Age less than 18 years old or older than 65 years old\n* Scheduled for deployment",{"count":250,"type":20},75,"It has been known that both estrogen and testosterone are the major sex steroids regulating bone metabolism and other physiological changes in both male and female, respectively. In postmenopausal women, osteoporosis is a major concern secondary to the lack of estrogen. These patients also experience a number of physiological changes that affect their life permanently to include hot flashes, irritability, difficulty concentrating, depression and mental confusion. In hypogonadal men, testosterone deficiency could lead to higher prevalence of depression, osteoporosis, fracture and frailty. Given the new military policy starting to support treatment for gender identity dysphoria military personnel, the number of transgender patients in our Endocrinology clinic has been slowly increasing over the past several months. These patients will require either testosterone replacement therapy or estrogen therapy to achieve their desired sexual characteristics. However, as mentioned above, the lack of estrogen or testosterone in female and male, respectively, could cause several issue in their body composition, cognitive function and quality of life. We designed this prospective case-control study to include patients with hypogonadism and the transgendered populations to learn about the long-term effects of these hormonal replacement therapies on bone density, fractures, memory\u002Fcognitive function and quality of life. This is a repetitive measures study taken at baseline, 6-months, and 12-months for three groups consisting of at least 75 subjects. The study will involve 3 arms, i.e. Group 1 primary\u002Fsecondary untreated hypogonadism, Group 2 male-to female (MTF), and Group 3 female-to-male (FTM) participants that are planning to start hormone replacement therapy as per standard clinical guidelines.",[253,254],"Hypogonadism","Gender Identity Dysphoria",[256,257,253],"Transgender","Gender dysphoria","2025-07-24",{"date":260,"type":31},"2025-07-29",{"date":262,"type":31},"2021-03-09",{"date":264,"type":20},"2025-08",{"name":37,"class":38},{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":47,"sex":71,"minAge":17,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":21,"phases":275,"briefSummary":277,"conditions":278,"keywords":280,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":39},"100545854","phase-4-bladder-botox-uti-antibiotic-prophylaxis-100545854","NCT06387329","Bladder Botox UTI Antibiotic Prophylaxis","Urinary Tract Infection Prophylaxis In Intradetrusor OnabotulinumtoxinA Procedures: A Randomized Controlled Trial","Inclusion Criteria:\n\n* All patients 18 years or older being seen at the WRNMMC Urogynecology clinic\n* Diagnosis of OAB or IC\u002FBPS\n* Planning to undergo intradetrusor onabotulinumtoxinA injection for treatment of their OAB or IC\u002FBPS\n* Ability to follow instructions and complete follow up\n\nExclusion Criteria:\n\n* Contraindication to nitrofurantoin (allergy, CrCl \\\u003C30mL\u002Fminute)\n* If performed in the operating room, the patient cannot undergo a concurrent procedure that would increase the risk of UTI or require an alternate antibiotic regimen (such as hysterectomy, prolapse repair, or anti-incontinence procedure)\n* Active UTI at the time of procedure\n* Neurogenic bladder\n* Recurrent UTI (3 in 12 month period or 2 in 6 months)\n* Post void residual bladder volume ≥150mL\n* Patient is already taking antibiotics at the time of the procedure\n* Contraindication to onabotulinumtoxinA (allergy, pregnancy, greater than 400 units of onabotulinumtoxinA received in the last 3 months)",{"count":274,"type":20},100,[276],"PHASE4","Overactive bladder (OAB) is a common condition with a prevalence of 17% in the general population that significantly affects quality of life. Intradetrusor onabotulinumtoxinA injections are an advanced therapy for OAB as well as interstitial cystitis\u002Fbladder pain syndrome (IC\u002FBPS). The most common adverse event following intradetrusor injection of onabotulinumtoxinA in urinary tract infection (UTI), which occurs in 8.6-48.1% of patients. To prevent UTIs, patients are given a course of antibiotics, however the ideal prophylactic regimen has not been determined for the timing, duration, and type of antibiotic. Four retrospective studies in the literature address this question with variable conclusions, and there are no prospective studies. Identifying the ideal regimen is important for preventing UTIs as well as minimizing antibiotic use to prevent adverse effects and development of antibiotic resistance.\n\nThe population to be studied will be female patients 18 years and older who are patients of the urogynecology and urology clinics at Walter Reed National Military Medical Center with a diagnosis of OAB or IC\u002FBPS and have chosen to be treated with intradetrusor onabotulinumtoxinA injections. It will be a non-blinded randomized controlled noninferiority trial in which the patients are randomly placed into 2 groups. The first group will receive a 3 day course of twice daily oral nitrofurantoin 100mg starting at the time of the procedure, and the second group will receive a single dose of 100mg oral nitrofurantoin at the time of the procedure.\n\nThe patients will be screened at the clinic at the time that they schedule their intradetrusor onabotulinumtoxinA injection appointment or by phone 1-2 weeks prior to their procedure. If the patient agrees to participate in the study then they will be instructed to give a urine sample for urinalysis and culture 1 week prior to the procedure appointment to exclude existing UTI. If a UTI is diagnosed at this time they must complete treatment prior to the procedure or will need to reschedule their procedure. On the day of the procedure patients will receive the clinic standard 10ml of 2% viscous lidocaine through the urethra 10-20 minutes prior to the procedure, and may be offered 5-10mg oral diazepam at the discretion of the treating physician. All patients will be given 200mg of phenazopyridine and 100mg of nitrofurantoin prior to the initiation of the procedure. The procedure will take place as directed by the treating physician per standard operating procedure.\n\nA urinalysis and urine culture will be placed for all study participants at time of their procedure appointment in case they have symptoms of UTI, and they will be instructed to follow up with the research team by phone if they have concerns for a UTI. Patients will be contacted 30-45 days after the procedure by phone, email, or message through genesis and asked about any UTI symptoms, UTI diagnoses and secondary outcomes during the 30 days following the procedure. Data will be analyzed for the primary outcome of UTI rates in the 30 days following intradetrusor onabotulinumtoxinA injection.",[279,26],"Overactive Bladder",[281,282,283],"Intradetrusor Onabotulinumtoxin A","Urinary tract infection","Antibiotic prophylaxis","2025-02-14",{"date":286,"type":31},"2025-02-19",{"date":288,"type":31},"2024-04-04",{"date":290,"type":20},"2025-06-30",{"name":37,"class":38},{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":298,"enrollmentInfo":299,"targetDuration":4,"studyType":21,"phases":301,"briefSummary":302,"conditions":303,"keywords":4,"overallStatus":210,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":4},"100578211","phase-4-difference-in-serum-estrogen-level-based-on-methods-of-vaginal-estrogen-application-fingertip-vs-applicator-use-in-post-menopausal-women-100578211","NCT06808347","Difference in Serum Estrogen Level Based on Methods of Vaginal Estrogen Application (fingertip Vs Applicator Use) in Post-menopausal Women","Inclusion Criteria:\n\n* patients who are postmenopausal for at least 1 year (since their last menses)\n* patients who qualify for treatment with vaginal estrogen cream and are willing to complete the treatment\n* English speaking patients\n* patients should be able to self-apply the vaginal estrogen cream using the applicator method and the fingertip application\n* Patients who are surgically menopausal\n* Military healthcare beneficiary status\n\nExclusion Criteria:\n\n* pre and perimenopausal women\n* contraindication to estrogen therapy (Deep vein thrombosis, history or active cancer)\n* women who are not able to self apply the vaginal estrogen cream\n* vaginal bleeding of unknown origin\n* women currently on hormone replacement therapy or vaginal estrogen therapy","100 Years",{"count":300,"type":20},110,[276],"Study the change in serum estrogen level based on the method of vaginal cream application (applicator vs fingertip application) and Measure patient satisfaction with vaginal estrogen cream application based on the method of application using a validated patient questionnaire (Likert scale).",[304,305],"Postmenopausal Atrophic Vaginitis","Genitourinary Syndrome of Menopause","2025-01-31",{"date":308,"type":31},"2025-02-05",{"date":310,"type":20},"2025-02-01",{"date":312,"type":20},"2025-09-30",{"name":37,"class":38},{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":320,"enrollmentInfo":321,"targetDuration":323,"studyType":102,"phases":4,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":39},"100572121","effect-of-intradetrusor-onabotulinumtoxina-injection-versus-conservative-management-on-female-sexual-function-in-patients-with-bladder-pain-syndrome-100572121","NCT06729151","Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome","Inclusion Criteria:\n\n* Female 18 years of age and older\n* For bladder pain syndrome participants: O'Leary Sant score 13 or greater\n* For healthy controls: O'Leary Sant score 12 or less\n* DEERS eligible (care provided by military health care system)\n\nExclusion Criteria:\n\n* Contraindications for bladder Botox\n* Current use of alternative treatment for bladder pain syndrome\n* Neurogenic bladder\n* Other urinary tract disease\n* Pelvic organ prolapse stage 3 or greater\n* Pregnancy or breastfeeding\n* Non-English speakers","99 Years",{"count":322,"type":20},159,"12 Weeks","Interstitial cystitis\u002Fbladder pain syndrome (IC\u002FBPS) is estimated to affect 3.3 to 7.9 million women aged 18 years and older in the United States. The American Urological Association (AUA) defines IC\u002FBPS as \"an unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms of more than six weeks duration, in the absence of infection or other identifiable causes\". IC\u002FBPS significantly impacts quality of life, with the individual domains of sexual function, anxiety and depression, sleep quality and work productivity being specifically affected. Significant sexual dysfunction in women with IC\u002FBPS has been consistently demonstrated across multiple international studies, with a prevalence ranging from 68% to 91%. In fact, among all patients with lower urinary tract symptoms, patients with a diagnosis of IC\u002FBPS had the highest levels of impaired sexual function, mostly due to dyspareunia. Recommended treatments for IC\u002FBPS include dietary and behavioral modifications, oral medications, bladder instillations, bladder hydrodistension, intradetrusor injection of onabotulinumtoxinA and major surgery. Scant research exists on how treating IC\u002FBPS affects sexual function. We are conducting a prospective cohort study to assess for improvement in sexual function following intravesical onabotulinumtoxinA injection versus conservative management for IC\u002FBPS.\n\nThe study will consist of three groups: intradetrusor onabotulinumtoxinA injection, conservative management and age-matched, healthy controls. All patients aged 18 years and older presenting to the Walter Reed National Military Medical Center (WRNMMC) Urogynecology clinic who are given a diagnosis of IC\u002FBPS and have an O'Leary Sant index questionnaire scoring 13 or greater will be eligible for the study. The primary study outcome is change in the pre- and 12-week post-treatment Female Sexual Function Index (FSFI). The secondary outcomes will include changes in the pre- and post-treatment O'Leary Sant index, Patient Global Impression of Improvement (PGI-I), Patient Global Impression of Severity (PGI-S), Pelvic Organ Prolapse\u002FIncontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR), Visual analog pain scale and 24-hour bladder diary (number of daily voids, number of nightly voids, incontinence episode). Adverse events will be monitored, including urinary tract infection or need for urinary catheterization due to urinary retention within 12 weeks of start of treatment. The age-matched, healthy control group will complete only one set of questionnaires to serve as a baseline comparison to the IC\u002FBPS groups. For between-groups comparisons, a sample size of 49 per group will have 80% power to detect a clinically important difference of 4 points if the standard deviation is 7 points, assuming a 5% two-sided significance level. We will therefore recruit 55 subjects per group to allow for approximately 10% attrition between the pre- and post-treatment assessments. This study will be powered to detect a difference between treatments groups, which has not yet been reported in the literature.",[26,326],"Female Sexual Dysfunction","2024-12-06",{"date":329,"type":31},"2024-12-11",{"date":331,"type":31},"2024-11-01",{"date":333,"type":20},"2026-12-31",{"name":37,"class":38},{"id":336,"slug":337,"hasResults":11,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":342,"targetDuration":4,"studyType":21,"phases":344,"briefSummary":345,"conditions":346,"keywords":351,"overallStatus":210,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":39},"100570628","phase-4-impact-of-preoperative-quadratus-lumborum-block-on-postoperative-opioid-consumption-after-laparoscopic-hysterectomy-100570628","NCT06709716","Impact of Preoperative Quadratus Lumborum Block on Postoperative Opioid Consumption After Laparoscopic Hysterectomy","Impact of Preoperative Quadratus Lumborum Block on Postoperative Opioid Consumption After Laparoscopic Hysterectomy: a Double-blinded Randomized Controlled Trial","Inclusion Criteria:\n\n* 18 years or older\n* scheduled to undergo laparoscopic hysterectomy\n* able to speak and understand English\n* DEERs eligible (eligible for healthcare within military heath system)\n* Owning a phone that can receive text messages or having internet access to complete questionnaires\n\nExclusion Criteria:\n\n* pre-operative opioid use\n* pre-operative pain management clinic patient\n* planned concomitant prolapse or incontinence procedure\n* planned concomitant non-gynecologic abdominal procedure (i.e. hernia repair)\n* inability to receive liposomal or non-liposomal bupivacaine\n* inability to receive non-steroidal anti-inflammatory drugs (NSAIDs)\n* inability to receive acetaminophen\n* inability to receive oxycodone\n* QL block not able to be performed bilaterally\n* planned or performed mini-laparotomy (incision greater than 2cm)\n* case converted to laparotomy",{"count":343,"type":20},76,[276],"The goal of this clinical trial is to learn if preoperative nerve block (quadratus lumborum \\[QL\\] block) works to improve pain control during and after laparoscopic hysterectomy. The main questions it aims to answer are:\n\nDoes QL block decrease the amount of narcotic medication needed during surgery? Does QL block decrease the amount of narcotic medication needed after surgery?\n\nResearchers will compare QL block to local injection of a numbing medication at each incision site (the current standard practice) to see if QL block works to decrease surgical pain.\n\nParticipants will be randomly assigned to receive one of the two following interventions:\n\n1. QL block before surgery with a long-acting numbing medicine (liposomal bupivacaine) and then injection of placebo (saline) at each incision site in the operating room.\n2. QL block before surgery with placebo (saline) and then injection of local numbing medicine (bupivacaine) at each incision site in the operating room.\n\nParticipants will also:\n\n* Visit the clinic\u002Fhospital for a pre-operative appointment, the surgical procedure, and a 4-6 week post-operative appointment (all standard visits even if not participating in research)\n* Complete a questionnaire electronically, or by phone, that takes \\\u003C10 minutes at the pre-operative appointment and on postoperative days 1, 3, 5, 14, and 4-6 weeks.",[347,348,349,350],"Postoperative Pain","Laparoscopic Hysterectomy","Nerve Block","Quadratus Lumborum Block",[352,353,354],"postoperative pain","quadratus lumborum block","laparoscopic hysterectomy","2024-11-25",{"date":357,"type":31},"2024-11-29",{"date":359,"type":20},"2024-12-01",{"date":361,"type":20},"2026-02",{"name":37,"class":38},{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":4,"eligibilityCriteria":369,"healthyVolunteers":47,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":370,"targetDuration":4,"studyType":21,"phases":372,"briefSummary":373,"conditions":374,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":39},"100456240","phase-4-vaginal-estradiol-vs-oral-beta-3-agonist-for-overactive-bladder-syndrome-100456240","NCT05221021","Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome","Vaginal Estradiol vs Oral Beta-3 Agonist for Treatment of Overactive Bladder Syndrome: A Single-Therapy, Double-Blind, Randomized Controlled Trial","Inclusion Criteria:\n\n* Raw score of 14 or more on OAB-q SF (adjusted score of 20)\n* Postmenopausal defined by not having a period for 12 months or bilateral oophorectomy a least 12 months status post procedure, or women with prior hysterectomy and preserved ovaries over age 55 years old or having a documented follicle stimulating hormone level greater than 40mIU\u002FmL.\n* Ability to speak and read English\n\nExclusion Criteria:\n\n* Contraindications to Vaginal Estrogen or Mirabegron\n* Post void residual \\>200mL or \\>1\u002F3 patient's total bladder volume\n* Currently on or previously taking anticholinergic or beta- 3 agonists within the past 1 month\n* Symptomatic pelvic organ prolapse greater than Stage 2, contraindication to vaginal estrogen therapy\n* Undiagnosed postmenopausal vaginal bleeding within the past 12 months\n* Current diagnosis of Multiple sclerosis, Parkinson's Disease, prior spinal cord injury, Spina Bifida, prior pelvic irradiation, Interstitial Cystitis, recurrent urinary tract infection.",{"count":371,"type":20},152,[276],"A single site, double-blinded, randomized controlled trial for postmenopausal women with urinary frequency, urgency, nocturia with or without urgency urinary incontinence symptoms. Patient's will be randomized between 0.01% vaginal estradiol cream with placebo oral pill or daily 50 milligrams oral Mirabegron with a placebo vaginal cream for 12 weeks.",[375],"Overactive Bladder Syndrome","2024-08-15",{"date":378,"type":31},"2024-08-19",{"date":380,"type":31},"2022-10-01",{"date":382,"type":20},"2027-01-30",{"name":37,"class":38},{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":47,"sex":71,"minAge":17,"maxAge":4,"enrollmentInfo":391,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":392,"conditions":393,"keywords":397,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":39},"100537249","the-effect-of-teprotumumab-on-thyroid-eye-disease-and-thyroid-dysfunction-100537249","NCT06275373","The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction","Teprotumumab","Inclusion Criteria:\n\n* only DOD beneficiaries\n* adult patients 18 years of age or older\n* adult patients with proptosis, ocular\u002Forbital pain, diplopia, lid\u002Forbital edema, or lid\u002Forbital erythema associated with autoimmune thyroid disease\n\nExclusion Criteria:\n\n* Patients with evidence of compressive optic neuropathy necessitating urgent orbital decompression or external beam radiation\n* patients with a history of uncontrolled diabetes mellitus\n* patients with a history\u002Fdiagnosis of uncontrolled inflammatory bowel disease\n* patients under age 18 years\n* patients who are pregnant or trying to become pregnant.",{"count":274,"type":20},"This protocol studies the clinical outcome of patients with active thyroid disease with visually significant signs and symptoms of proptosis, pain, diplopiam lid\u002Forbital edema, or lid\u002Forbital erythema recommended for treatment with teprotumumab infusion (Tepezza®). Patients recommended for treatment will be evaluated by an oculoplastic surgeon (Dr. Eva Chou) and endocrinologist (Dr. Thanh Hoang).",[394,395,396],"Thyroid Eye Disease","Graves Ophthalmopathy","Graves Disease",[398,399,400],"Thyroid eye disease","Graves ophthalmopathy","Graves disease","2024-02-16",{"date":403,"type":31},"2024-02-23",{"date":405,"type":31},"2021-05-12",{"date":407,"type":20},"2027-12-12",{"name":37,"class":38},{"id":410,"slug":411,"hasResults":11,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":47,"sex":71,"minAge":17,"maxAge":4,"enrollmentInfo":416,"targetDuration":4,"studyType":21,"phases":418,"briefSummary":419,"conditions":420,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":39},"100364076","phase-4-standard-injections-versus-reduced-injections-for-intravesical-onabotulinumtoxina-treatment-of-overactive-bladder-100364076","NCT04020510","Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder","Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA for Treatment of Idiopathic and Neurogenic Overactive Bladder: a Randomized Trial","Inclusion Criteria:\n\n* Males or Females ≥ 18 years of age\n* Predominant complaint of urinary urgency, urinary frequency or urge incontinence\n* Failed at least one medication (inadequate or poorly tolerated response) or behavior modification technique (timed voiding, pelvic floor physical therapy, etc.), or decline such interventions\n* Willingness to perform self-catheterization in the event of symptomatic urinary retention\n* Ability to follow study instructions and likely to complete all required follow-up\n\nExclusion Criteria:\n\n* Concurrent use of oral medications for treatment of OAB (anticholinergics or beta 3 agonists).\n* Post void residual volume \\> 200 ml\n* Symptomatic prolapse \\> POP-Q (Pelvic Organ Prolapse Quantification) stage 2 or greater that is untreated\n* Evidence of active UTI (bladder infection)\n* Any previous use of intradetrusor botulinum toxin (onabotulinumtoxinA or abobotulinumtoxinA) within the preceding 6 months\n* Use of \\>\u002F= 400 units bontulinum toxin in the preceding 3months in other areas of the body\n* Procedure performed in the main operating room (not outpatient setting)\n* Concurrent diagnosis of interstitial cystitis\u002Fpainful bladder syndrome\n* Females who are pregnant or planning a pregnancy during the study or who think that they may be pregnant at the start of the study, or females of childbearing potential who are unable or unwilling to use a reliable form of contraception during the study.\n* Any medical condition that may put the subject at increased risk with exposure to botulinum-A toxin, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis\u002Fmotor neuron disease, neuropathy, renal stones, or any other disorder that might interfere with neuromuscular function\n* Known allergy or sensitivity to any of the components of onabotulinumtoxinA\n* Concurrent participation in another investigational drug or device study that could impact the results\n* Any condition or situation that, in the investigator's opinion, may put the subject at significant risk, confound the study results, or interfere significantly with the subject's participation in the study",{"count":417,"type":20},184,[276],"OnabotulinumtoxinA is an effective treatment for both idiopathic and neurogenic overactive bladder and was FDA approved for this indication in 2013. The standard technique for injecting onabotulinumtoxinA into the detrusor is mixing 100 units of onabotulinumtoxinA into 10mL of injectable normal saline and injecting 20 sites with 0.5mL in the posterior wall of hte bladder for idiopathic overactive bladder and mixing 200 units into 30mL and injecting 30 sites with 1mL for neurogenic overactive bladder. The purpose of this study is to compare the efficacy of a technique using a reduced number of injections with the same dosage of onabotulinumtoxinA to the standard technique. The hypothesis is that the reduced technique will not be inferior in terms of efficacy as the standard technique and that there will be a lower incidence of urinary tract infections and urinary retention requiring catheterization post-procedure.",[279],"2020-04-23",{"date":423,"type":31},"2020-04-28",{"date":425,"type":31},"2019-07-01",{"date":427,"type":20},"2021-12-31",{"name":37,"class":38},""]